FierceBiotechCodex · 实盘不做把握 5/10不做原因:无法执行
北京时间·🕒 发布 21:24:00(美东 09:24)时区推断·⟳ 抓取 22:18:25·⚡ 决策 08-25 22:43:28 +25m03s·62.8 天前
海思科将临床前自免资产授权给Sentivera，交易潜在总额超15亿美元
事件本身对海思科为明确利好，但缺少强制要求的真实行情、停牌/成交状态和先例事件研究结果，不能给出可回测ENTER订单。
📄 原文FierceBiotech↗ 原文
Founded by Metsera backers, Sentivera emerges with $1.5B inflammatory disease deal
Having set Metsera on its journey to a $10 billion takeover, Arch Venture Partners and Population Health Partners have…
不做 海思科（002653.SZ）
事件方向明确偏多，但缺少生产行情工具返回的实时价格、停牌状态、近20日抢跑轨迹和event_study结果，按交易契约不能给可执行ENTER。
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
研究档案
结论摘要
海思科把早期自免资产授权给由ARCH和Population Health支持的Sentivera，获得约7589万美元首付款及股权对价，相当于约2025年收入的12%左右，并保留大中华区权益；但资产仍处临床前/IND早期，14.6亿美元里程碑兑现周期长且不确定，且未能取得可用于下单的实时行情与事件研究输出，因此不生成交易腿。
消息传播链
- 海思科官方通稿披露与Sentivera签署独占许可，披露7589万美元首付款及股权对价、最高14.6亿美元里程碑和分级特许权使用费。
- FierceBiotech报道Sentivera由Metsera相关投资方支持，并强调该资产为Type 2炎症方向小分子。
- 财联社盘后转发海思科公告，披露首付款、股权对价、最高里程碑及交易尚需审批。市场反应:报道页显示海思科当日涨幅约0.25%，说明A股盘中尚未明显交易该盘后公告。
- 新浪财经转载界面新闻，补充说明资产为口服小分子制剂、王俊民参投Sentivera且构成关联交易。
关键理由
- 7589万美元首付款及股权对价对海思科2025年43.88亿元收入和2.60亿元归母净利润有可见量级，短线利好明确。
- ARCH和Population Health参与的新公司结构提高了海外开发融资和BD兑现预期，且海思科保留大中华区权益。
- 标的仍处临床前/IND早期，14.6亿美元里程碑主要是远期或有收入，不能按满额资本化。
主要风险
- 交易尚需股东会批准，且新药研发和海外开发失败会导致后续里程碑无法兑现。
- 未取得真实行情和近20日轨迹，无法判断公告前是否已有抢跑或次日是否高开透支。
反向证据
先例如何影响了这次决策
对本次决策的影响:先例使本次结论从强利好降为中等把握利好，并因无法测算价格反应而不生成ENTER。
方向:同一公司历史license-out样本支持方向偏正，但相似度不足以单独支撑下单。
涨幅量级:未能调用event_study取得真实1/3/5日超额收益，不能用先例校准tp/sl。
形态:海思科今年已有多次大额授权，存在市场对BD国际化逐步预期化的风险。
历史先例(按相似度)
- 相似度 7/10 002653.SZ 2026-06-22 Nuvectis取得海思科两项资产大中华区外权益，披露4000万美元前期款及约14亿美元潜在里程碑。 原文 ↗
应测海思科002653.SZ在2026-06-22后A股反应
⚠非首发(转载/聚合)·来源层级不符(声明wire/实为aggregator) — 该行涨幅别用来定止盈止损
相似度依据:同一公司、同为海外license-out且总额约14亿美元，但资产阶段和交易对手不同。
经验:海思科已有多次大额授权交易，新增交易仍有利好但市场可能逐步提高预期。 - 相似度 6/10 002653.SZ 2026-01-09 AirNexis以4000万美元现金加19.9%股权获得海思科AN01/HSK39004大中华区外权益，并含最高9.55亿美元里程碑。 原文 ↗
应测海思科002653.SZ在2026-01-09后A股反应
相似度依据:同一公司、同为海外NewCo获得资产授权，但为COPD临床阶段资产，机制和阶段不同。
经验:NewCo结构可提升海外开发预期，但权益和里程碑兑现仍取决于后续临床推进。
原文全文
展开原文 · 1,940 字
Having set Metsera on its journey to a $10 billion takeover, Arch Venture Partners and Population Health Partners have powered their new startup—Sentivera—to a licensing deal worth up to $1.5 billion.
Arch and Population Health launched Metsera in 2022. Having exited stealth with $290 million in 2024, the biotech became the subject of a bidding war between Novo Nordisk and Pfizer last year. Pfizer won, enabling the U.S. Big Pharma to put Metsera’s assets at the center of its efforts to establish a presence in the blockbuster obesity market.
The investors moved quickly to replicate the success. Twelve days after Pfizer closed the Metsera deal, Sentivera incorporated in Delaware. Sentivera initially kept a low profile, but the inking of a licensing deal with a drugmaker traded on the Shanghai Stock Exchange has thrust the startup into the spotlight.
Sentivera is paying (PDF) Haisco Pharmaceutical $40 million in cash upfront for an inflammatory disease drug candidate that recently received clearance to enter clinical development in China. Haisco will also receive Sentivera stock valued at almost $36 million, giving it a 17.5% stake in the biotech. Wang Junmin, the billionaire chair of Haisco, contributed $5 million to Sentivera’s $83 million funding round.
Haisco has retained the rights to the drug candidate in Greater China. With a stake in Sentivera and a deal featuring up to $1.46 billion in milestones, Haisco is positioned to profit as its partner advances the asset in the rest of the world.
The drug at the center of the deal remains shrouded in mystery. Haisco described the candidate as a small molecule that inhibits development and progression of Type 2 inflammatory diseases. Seen in conditions such as asthma and eczema, Type 2 inflammation is a form of immune response seen in conditions such as asthma and eczema, with Sanofi and Regeneron’s Dupixent among the drugs that target this type of inflammation.
Arch and Population Health launched Metsera in 2022. Having exited stealth with $290 million in 2024, the biotech became the subject of a bidding war between Novo Nordisk and Pfizer last year. Pfizer won, enabling the U.S. Big Pharma to put Metsera’s assets at the center of its efforts to establish a presence in the blockbuster obesity market.
The investors moved quickly to replicate the success. Twelve days after Pfizer closed the Metsera deal, Sentivera incorporated in Delaware. Sentivera initially kept a low profile, but the inking of a licensing deal with a drugmaker traded on the Shanghai Stock Exchange has thrust the startup into the spotlight.
Sentivera is paying (PDF) Haisco Pharmaceutical $40 million in cash upfront for an inflammatory disease drug candidate that recently received clearance to enter clinical development in China. Haisco will also receive Sentivera stock valued at almost $36 million, giving it a 17.5% stake in the biotech. Wang Junmin, the billionaire chair of Haisco, contributed $5 million to Sentivera’s $83 million funding round.
Haisco has retained the rights to the drug candidate in Greater China. With a stake in Sentivera and a deal featuring up to $1.46 billion in milestones, Haisco is positioned to profit as its partner advances the asset in the rest of the world.
The drug at the center of the deal remains shrouded in mystery. Haisco described the candidate as a small molecule that inhibits development and progression of Type 2 inflammatory diseases. Seen in conditions such as asthma and eczema, Type 2 inflammation is a form of immune response seen in conditions such as asthma and eczema, with Sanofi and Regeneron’s Dupixent among the drugs that target this type of inflammation.
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
这条决策早于决策账本(2026-10-08 起逐条追加),没有追加记录。